Despite an Increasing Volumes, the US Dyslipidemia Market to Decline by a CAGR of 10% during 2010-2016

A new report from IMARC expects the US dyslipidemia market to decrease by value in the coming years. End Quote

(1888PressRelease) September 24, 2011 - Despite increasing volumes, the market for dyslipidemia drugs in the US is expected to decline by a CAGR of 10% during 2010 and 2015. IMARC Group - one of the world's leading research and advisory firms, in its new report entitled "US Cholesterol Lowering Agents Market Report & Forecast: On the Edge of a Patent Cliff" finds that from around 150 Million patients in 2010, the total number of dyslipidemia patients in the US will reach 169 Million by 2020. Findings from the report also suggest that diagnosis and drug treatment rates for dyslipidemia will also increase during the period. This is expected to significantly increase the total size of the drug treated patient pool in the US. Despite increasing volumes, however, the report expects a patent cliff of blockbuster drugs coupled by a thin pipeline to erode this market of sales worth more than US$ 8.7 billion in the next six years.

IMARC's new report entitled "US Cholesterol Lowering Agents Market Report & Forecast: On the Edge of a Patent Cliff" provides an analytical and statistical insight into the US Cholesterol Lowering agents Market. The study that has been undertaken using both desk-based as well as qualitative primary research has analyzed the following aspects of this market:

Key Aspects Analyzed:

Understanding the Epidemiology of Dyslipidemia in the US:
Focus of the Analysis:
• Current and future size of the dyslipidemia patient pool
• Current and future prevalence of dyslipidemia
• Current and future diagnosis rates for dyslipidemia
• Current and future drug treatment rates for dyslipidemia

Comprehensive Evaluation of the US Cholesterol Lowering Agents Market:

Classes Covered: Statins, Fixed Dose Combinations, Ion Exchange Resins, Fibrates, Other Cholesterol Triglyceride Regulators, Omega-3 Acid Ethyl Esters and CETP Inhibitors

Molecules Covered: Atorvastatin, Rosuvastatin, Simvastatin, Pravastatin, Fluvastatin, Lovastatin, Pitavastatin, Ezetimibe/Simvastatin, ER Niacin/Simvastatin, Atorvastatin/Amlodipine, ER Naicin/Laropiprant, Ezetimibe/Atorvastatin, ER Niacin/Laropiprant/Simvastatin, Colesevelam, Cholestyramine, Colestipol, Fenofibrate, Fenofibric Acid, Gemfibrozil, Dalcetrapib, Anacetrapib

Focus of the Analysis for Each Class & Molecule:
• Drug Overview
• Historical Sales
• Key Players and Brands in the Market
• Patent Expiries and Generic Launch
• Sales Forecast

Comprehensive Evaluation of Generic Opportunities in the US Cholesterol Lowering Agents Market:
• Historical Patent Expiries and the Evolution of Generic Drugs
• Historical Value and Volume share of Brands and Generics
• Future Patent Expiries and Generic Launches
• Value and Volume Forecasts for Brands and Generics

Information Sources:
Information has been sourced from both primary and secondary sources:
• Primary sources include industry surveys and face to face/telephone interviews with industry experts.
• Secondary sources include proprietary databases and search engines. These sources include company websites and reports, books, trade journals, magazines, white papers, industry portals, government sources and access to more than 4000 paid databases.

Table of Contents

1. Research Methodology & Market Definitions
2. Executive Summary
3. Epidemiology
3.1 Prevalence of Dyslipidemia
3.2 Diagnosis & Drug Treatment Rates
4. The US Cholesterol Lowering Agents Market
4.1 Current Trends (2005-2010)
4.2 Market Forecast (2011-2016)
5. The US Dyslipidimia Market: Performance of Various Classes
5.1 Statins
5.1.1 Key Trends (2005-2010)
5.1.2 Share of Key Players
5.1.3 Sales & Forecast of Key Molecules
5.1.3.1 Atorvastatin (Lipitor) Historical Sales & Forecast
5.1.3.2 Rosuvastatin (Crestor) Historical Sales & Forecast
5.1.3.3 Simvastatin (Zocor) Historical Sales & Forecast
5.1.3.4 Pravastatin (Pravachol) Historical Sales & Forecast
5.1.3.5 Fluvastatin (Lescol) Historical Sales & Forecast
5.1.3.6 Lovastatin (Mevacor) Historical Sales & Forecast
5.1.3.7 Pitavastatin (Livalo) Historical Sales & Forecast
5.2 Fixed Dose Combinations
5.2.1 Key Trends
5.2.2 Share of Key Players
5.2.3 Sales & Forecast of Key Molecules
5.2.3.1 Ezetimibe/Simvastatin (Vyotrin) Historical Sales & Forecast
5.2.3.2 ER Niacin/Simvastatin (Simcor) Historical Sales & Forecast
5.2.3.3 Atorvastatin/Amlodipine (Caduet) Historical Sales & Forecast
5.2.3.4 ER Naicin/Lapropiprant (Tredaptive) Historical Sales & Forecast
5.2.3.1 Ezetimibe/Atorvastatin (MK-653C) Sales Forecast
5.2.3.2 ER Niacin/Laropiprant/Simvastatin (MK-0524B) Sales Forecast
5.3 Ion Exchange Resins
5.3.1 Key Trends
5.3.2 Share of Key Players
5.3.3 Sales & Forecast of Key Molecules
5.3.3.1 Colesevelam (Welchol) Historical Sales & Forecast
5.3.3.2 Cholestyramine (Questran) Historical Sales & Forecast
5.3.3.3 Colestipol (Colestid) Historical Sales & Forecast
5.4 Fibrates Market
5.4.1 Key Trends
5.4.2 Share of Key Players
5.4.3 Sales & Forecast of Key Molecules
5.4.3.1 Fenofibrate (Tricor) Historical Sales & Forecast
5.4.3.2 Fenofibric Acid (Trilipix) Historical Sales & Forecast
5.4.3.3 Gemfibrozil (Lopid) Historical Sales & Forecast
5.5 Other Cholesterol Triglyceride Regulators
5.5.1 Key Trends
5.5.2 Share of Key Players
5.5.3 Sales & Forecast of Key Molecules
5.5.3.1 Ezetimibe (Zetia) Historical Sales & Forecast
5.5.3.2 Nicotinic Acid (Niacin/Niaspan) Historical Sales & Forecast
5.6 Omega-3 Acid Ethyl Esters (Lovaza)
5.6.1 Key Trends
5.6.2 Share of Key Players
5.6.3 Sales Forecast
5.7 CETP Inhibitors
5.7.1 Sales Forecast for Key Molecules
5.7.1.1 Dalcetrapib (RO4607381/JTT-705) Sales Forecast
5.7.1.2 Anacetrapib (MK-0859) Sales Forecast
6. Genericization in the US Dyslipidemia Market
6.1 Generic Evolution in the US Dyslipidemia Market
6.2 Patent Expiries & Size of the Generic Opportunity
6.3 Forecast for Dyslipidemia Generics
7. Key Company Profile
7.1 Pfizer
7.2 Merck & Co
7.3 Astrazeneca
7.4 Abbott
7.5 Glaxosmithkline

To buy the complete report or to get a free sample:
Call: +91-120-425-6531 (Asia), +44-844-774-9660 (Europe), +1-631-791-1145 (America)
Email: sales ( @ ) imarcgroup dot com
For more information please visit: www.imarcgroup.com

###

space

Other Related Press Releases

Totally Nourish Cutest Pet Facebook Competition Winners Announced by Totally Nourish
Despite an Increasing Volumes, the US Dyslipidemia Market to Decline by a CAGR of 10% during 2010-2016 by Imarc Group
NHS Rotherham Operates Inhouse TV with ONELAN by Onelan Ltd